On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

House passes 21st Century Cures Act; Omeros snags EU recommendation for Omidria;

@FierceBiotech: Amgen's PCSK9 contender lines up for first place in the blockbuster EU race. Story | Follow @FierceBiotech @JohnCFierce: What's your list of top 5 public biotechs? (Potential,...

GSK submits Japan regulatory application for mepolizumab in severe eosinophilic asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for mepolizumab as an add-on maintenance...

Omidria® Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use

SEATTLE, May 22, 2015 -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both...

China's Cellular Biomedicine spikes on early CAR-T data

Shanghai drug developer Cellular Biomedicine reported some positive results from a small study of its in-development cancer immunotherapy, sending its shares up more than 15% on Friday.

Cellular Biomedicine Group Announces Positive Phase I Results From CAR-T CD30 Immuno-Oncology Clinical Development Program

SHANGHAI, China and PALO ALTO, Calif., May 22, 2015 -- Cellular Biomedicine Group Inc. (CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective...

Chinese drugmakers snag antibody expert Ambrx in joint buyout

A group of Chinese biotech heavyweights are banding together to buy Ambrx, R&D partner to the likes of Bristol-Myers Squibb and Merck, in hopes of making the company a go-to collaborator in their native country.

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx

SHANGHAI -- A consortium ("the Consortium") consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited's healthcare fund...

Novartis' duo of COPD drugs clears Phase III on the path to an FDA decision

Novartis, working to get a pair of Europe-approved COPD treatments onto the U.S. market, reported some positive Phase III data while awaiting final word from the FDA.

Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237

QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies showed...